Frizzled-2

Frizzled-2 Informations sur la molécule

Nom anglais	Frizzled-2	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1	Alias de la cible	Frizzled Class Receptor 2，Frizzled 2， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 2，FzE2，Fz-2
Phase de R&D la plus avancée	Phase 1 Clinical

Nom anglais	Frizzled-2
Alias de la cible	Frizzled Class Receptor 2，Frizzled 2， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 2，FzE2，Fz-2
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Phase 1 Clinical

Frizzled-2 Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (2)
Étiquette
Fc Tag (2)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
FZ2-H5251	Human	HEK293	Human Frizzled-2 / FZD2 Protein, Fc Tag				Ajouter au panier
FZ2-H5255	Human	HEK293	Human Frizzled-2 / FZD2 (24-190) Protein, Fc Tag				Ajouter au panier

Quantité totale2

Frizzled-2Contexte de la molécule

Frizzled-2 (FZD2) is also known as FzE2, which belongs to the G-protein coupled receptor Fz/Smo family. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. FZD2 contains one FZ (frizzled) domain. FZD2 may be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. The Lys-Thr-X-X-X-Trp motif of FZD2 interacts with the PDZ doman of Dvl (Disheveled) family members and is involved in the activation of the Wnt/beta-catenin signaling pathway.

Frizzled-2Alias de la molécule

FZD2,Frizzled-2,Fz-2,hFz2,FzE2

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Vantictumab	OMP-18R5; anti-Fzd7	Phase 1 Clinical	Bayer AG, Oncomed Pharmaceuticals Inc	Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Osteopetrosis; Pancreatic Neoplasms; Solid tumours	Details